SIU 2017: Salvage Extended Lymph Node Dissection in Patients with Low Volume Lymph Node Recurrence after Primary Local Treatment: Multicenter Experience

Lisbon, Portugal (UroToday.com) PSMA-PET Scan is becoming increasingly popular in the setting of biochemical recurrence after PCa definitive therapy (XRT or RP) for identification of low-volume metastatic disease. However, while better than conventional imaging, it is not perfect.

In this abstract, the authors present their small series of 57 patients at 3 institutions who underwent salvage PLND for single PET avid LN positive on Choline-PET/CT scan following definitive primary therapy for localized PCa. This was a retrospective assessment of their results. 77% were after Radical prostatectomy, 23% were after either EBRT or Brachytherapy. In all cases, patients underwent extended node dissection – including pelvic nodes, iliac nodes and para-aortic nodes (picture of template provided). Hormonal therapy (HT) was only initiated if PSA > 0.2 1-month after surgery. Complete PSA remission defined as PSA < 0.2, and HT was only initiated after PSA progression (Biochemical recurrence).

Of the 57 patients, median PSA was 6.6 pre-operatively, primary PCa had been Gleason 6 (44%), 7 (38%) and Gleason 8-10 (18%). Time to SPND from definitive therapy was approximately 2 years.

Mean follow-up after SPLND was 16.8 months. Median number of nodes removed: 16. LN positivity was confirmed in 93% of patients; 7% did not have histologically confirmed prostate cancer. Importantly 45.3% of cases had nodes discovered in the ePLND that were not identified on the PSMA PET scan; median number of LN mets removed was 3 (even though only 1 was seen pre-operatively). 82.5% had PSA decline. Complete remission without any additional therapy was observed in 23% of patients. As can be expected, PSA decline >90% 1-month post-op was a strong predictor of good long-term response. 3-year BCR-free survival was 21%.

PSA decline:

conference image3

An important addition to the literature supporting sPLND. Clearly some patients benefit from removal of oligometastatic disease, with delay to HT or no HT.

A major limitation of the study is the use of choline-PET/CT, which is now known to be suboptimal compared to PSMA PET scan.

Speaker(s): Kirill Nyushko, Russia

Institution(s): Russian Scientific Radiological and Surgical Center, Russia

Written by: Thenappan Chandrasekar, MD, Clinical Fellow, University of Toronto, twitter: @tchandra_uromd, at the 37th Congress of Société Internationale d’Urologie - October 19-22, 2017- Lisbon, Portugal
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe